Rezolute, Inc. (RZLT)

NASDAQ: RZLT · IEX Real-Time Price · USD
1.36
+0.01 (0.74%)
Sep 27, 2023, 4:30 PM EDT - Market closed
0.74%
Market Cap 50.09M
Revenue (ttm) n/a
Net Income (ttm) -51.79M
Shares Out 36.83M
EPS (ttm) -1.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 15,079
Open 1.35
Previous Close 1.35
Day's Range 1.34 - 1.41
52-Week Range 1.30 - 2.97
Beta 2.13
Analysts Strong Buy
Price Target 11.00 (+708.82%)
Earnings Date Nov 8, 2023

About RZLT

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as Ant... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 51
Stock Exchange NASDAQ
Ticker Symbol RZLT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for RZLT stock is "Strong Buy." The 12-month stock price forecast is $11.0, which is an increase of 708.82% from the latest price.

Price Target
$11.0
(708.82% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress

Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023 Planning to initiate Phase 3 Study for RZ358 (“sunRIZE study”) in the fourth quarter of 2023

13 days ago - GlobeNewsWire

Rezolute to Participate in Upcoming Investor Conferences in September

REDWOOD CITY, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential t...

22 days ago - GlobeNewsWire

Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism

Study to be initiated in Europe and other ex-US geographies in Q4 2023, with topline results expected 1H 2025 Conference call scheduled today at 4:30 p.m. ET  REDWOOD CITY, Calif.

3 months ago - GlobeNewsWire

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innov...

Other symbols: OCS
4 months ago - Newsfile Corp

Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023 The Company is poised to commence Phase 3 for RZ358 in the third quarter of calendar year 2023

4 months ago - GlobeNewsWire

Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema

RZ402 is an oral therapy being developed as a potential alternative to anti-vascular growth factor (anti-VEGF) injections into the eye RZ402 is an oral therapy being developed as a potential alternati...

6 months ago - GlobeNewsWire

Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert

Conference call and webcast to be held on Wednesday, March 22 at 4:30 pm EDT Conference call and webcast to be held on Wednesday, March 22 at 4:30 pm EDT

7 months ago - GlobeNewsWire

Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress

Initiated Phase 2 proof-of-concept study of RZ402

8 months ago - GlobeNewsWire

Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema

RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye RZ402 is an oral therapy being developed as a potential alternative to invasive a...

10 months ago - GlobeNewsWire

Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress

Phase 2 proof-of-concept study of RZ402 expected to be initiated by the end of this year

11 months ago - GlobeNewsWire

Rezolute to Present at the Jefferies London Healthcare Conference

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to...

11 months ago - GlobeNewsWire

Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting

REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to...

1 year ago - GlobeNewsWire

Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress

Announced a $130 million registered direct offering and concurrent private placement priced at-the-market

1 year ago - GlobeNewsWire

Rezolute Announces Presentation at the 60th Annual ESPE Meeting

Data from Phase 2b RIZE Study in congenital hyperinsulinism will be presented in oral presentation

1 year ago - GlobeNewsWire

Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer

REDWOOD CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to...

1 year ago - GlobeNewsWire

Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress

Announced a $130 million registered direct offering and concurrent private placement

1 year ago - GlobeNewsWire

Rezolute to Host Corporate Update Call on May 4, 2022

Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ET Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ET

1 year ago - GlobeNewsWire

Rezolute, Inc. Announces Closing of Registered Direct Offering

REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to ...

1 year ago - GlobeNewsWire

Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market

REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to ...

1 year ago - GlobeNewsWire

Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism

Results Presented Today at the Pediatric Endocrine Society's 2022 Annual Meeting Results Presented Today at the Pediatric Endocrine Society's 2022 Annual Meeting

1 year ago - GlobeNewsWire

RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022

Rezolute to host conference call presentation and discussion of the data on Sunday, May 1 at 2:30 p.m. ET

1 year ago - GlobeNewsWire

Rezolute Joins the Rare Disease Company Coalition

Rezolute joins group aimed at helping advance timely access to life-saving therapies for those impacted by rare diseases Rezolute joins group aimed at helping advance timely access to life-saving ther...

1 year ago - GlobeNewsWire

Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism

The RIZE study demonstrated highly significant improvements in hypoglycemia and good safety and tolerability

1 year ago - GlobeNewsWire

Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME

Phase 2 proof-of-concept study anticipated in 2H 2022 Phase 2 proof-of-concept study anticipated in 2H 2022

1 year ago - GlobeNewsWire

Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress

Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022 Topline results from RZ358 Phase 2b and RZ402 Phase 1b studies expected before the end of Q1 2022

1 year ago - GlobeNewsWire